Skip to main content

Table 1 Patient Demographics

From: A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

Characteristic Cohort 1 Cohort 2
Vemurafenib 6 weeks (N = 38) Vemurafenib 7–18 weeks (N = 15)
Age (yr)
 Mean (SD) 48.6 (12.79) 48.5 (13.90)
 Median 50.5 48.0
 Range 21–73 26–67
Gender – no. (%)
 Male 15 (39.5) 6 (40.0)
 Female 23 (60.5) 9 (60.0)
Race – no. (%)
 White 35 (92.1) 15 (100.0)
 Decline 2 (5.3) 0 (0.0)
 Other 1 (2.6) 0 (0.0)
Metastasis stage – no. (%)
 M1a 9 (23.7) 2 (13.3)
 M1b 13 (34.2) 3 (20.0)
 M1c 16 (42.1) 10 (66.7)
LDH level – no. (%)
  ≤ ULN 17 (44.7) 5 (33.3)
  > ULN 17 (44.7) 8 (53.3)
 Not measured 4 (10.5) 2 (13.3)
Prior therapy – no. (%)
 Surgery 34 (89.5) 13 (86.7)
 Radiation 7 (18.4) 8 (53.3)
 Chemotherapy 4 (10.5) 1 (6.7)
 Anti-PD1/PDL1 0 0
Mutation – no. (%)
 BRAF 38 (100.0) 15 (100.0)
 cKIT 1 (2.6) 0 (0.0)
 Other 1 (2.6) 0 (0.0)
Performance Status
 0 24 (63.2) 8 (53.3)
 1 14 (36.8) 7 (46.7)
  1. Race of ‘Other’ had the description ‘Not specified’ recorded